Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BIO-TECHNE (TECH) Capital Expenditures: 2009-2025

Historic Capital Expenditures for BIO-TECHNE (TECH) over the last 17 years, with Jun 2025 value amounting to $31.0 million.

  • BIO-TECHNE's Capital Expenditures fell 41.53% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.2 million, marking a year-over-year decrease of 53.48%. This contributed to the annual value of $31.0 million for FY2025, which is 50.69% down from last year.
  • Per BIO-TECHNE's latest filing, its Capital Expenditures stood at $31.0 million for FY2025, which was down 50.69% from $62.9 million recorded in FY2024.
  • Over the past 5 years, BIO-TECHNE's Capital Expenditures peaked at $62.9 million during FY2024, and registered a low of $31.0 million during FY2025.
  • Its 3-year average for Capital Expenditures is $44.0 million, with a median of $38.2 million in 2023.
  • In the last 5 years, BIO-TECHNE's Capital Expenditures soared by 64.41% in 2024 and then slumped by 50.69% in 2025.
  • Over the past 5 years, BIO-TECHNE's Capital Expenditures (Yearly) stood at $44.3 million in 2021, then climbed by 1.37% to $44.9 million in 2022, then dropped by 14.84% to $38.2 million in 2023, then soared by 64.41% to $62.9 million in 2024, then crashed by 50.69% to $31.0 million in 2025.